Physician profile
Danial Daneshvar
NPI 1528413424
$2,311.29
in general payments reported to CMS, 2019-2025
24 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $1,026 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Education: $16.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.45 |
| Education | $16.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $327.63 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $270.59 | 2023-2025 | |
| Madrigal Pharmaceuticals | $268.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $179.93 | 2023-2025 | Ibsrela |
| Abbvie INC. | $173.19 | 2024-2025 | |
| Intra-Sana Laboratories | $150.00 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.47 | 2024-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $119.08 | 2023-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $79.00 | 2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $64.84 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $63.36 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.70 | 2024 | Cyltezo |
| Lilly USA, LLC | $54.31 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $53.77 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $49.28 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $47.13 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $44.64 | 2023-2025 | Suflave |
| Qol Medical, LLC | $40.66 | 2024 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $39.36 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $34.68 | 2024-2025 | Voquezna |
| Vivus LLC | $20.27 | 2025 | Pancreaze |
| Genzyme Corporation | $17.77 | 2025 | |
| Celltrion USA INC. | $16.84 | 2024 | Zymfentra |
| Celgene Corporation | $14.19 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danial Daneshvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.